Cincera Therapeutics
Cincera Therapeutics is a pre-clinical biotech company developing targeted therapies for fibrotic diseases, with an initial focus on genetic kidney diseases. Leveraging its lead compound CIN244, a first-in-class MRTF pathway inhibitor, Cincera aims to halt disease progression by modulating key fibrotic signalling mechanisms.
Over 30 million people worldwide suffer from fibrotic kidney diseases, which are progressive, life-threatening, and often genetically driven. Existing treatments are ineffective and do not address the underlying fibrotic mechanisms.
Cincera’s approach—targeting key drivers of fibrosis—has the potential to transform care by slowing or halting disease progression, preserving kidney function, and improving long-term outcomes for millions of patients.
